| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
ZFHX3/ATBF1 was identified to inhibit expression AFP and to promote cell differentiation. Examination of ZFHX3 revealed its reduction in 14 of 110 renal cell cancer (RCC) and they had poorer prognosis. ZFHX3 is known to suppress stat-3 function by binding PIAS3. Stat-3 transactivates IL-6 gene, and RCC cases with IL-6 elevation show shooter survival. A704, a RCC cell line, with high IL-6 production and high phosphorylated stat-3, were treated with retinoic acid which is potential ZFHX3 inducer. As a result, elevation of ZFHX3 and inhibition of stat-3 function, concomitant with decreased cell proliferation were observed.
|
